Highlights From the 62nd ASH Annual Meeting and Exposition
Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults With Severe or Moderate-Severe Hemophilia B: Two Year Data From a Phase 2b Trial
Annette von Drygalski, MD, Pharm D1, Adam Giermasz, MD, PhD2, Giancarlo Castaman, MD3, Nigel S. Key, MD4,5, Susan U. Lattimore, R.N.6, Frank W.G. Leebeek, MD, PhD7, Wolfgang A. Miesbach, MD8, Michael Recht, MD, PhD9, Esteban Gomez, MD10, Robert Gut, MD, PhD11, and Steven W. Pipe, MD12
1Department of Medicine, Division of Hematology/Oncology, UC San Diego Health, San Diego, CA
2University of California Davis, Sacramento, CA
3Azienda Ospedaliera Universitaria Careggi, Florence, Italy
4University of North Carolina at Chapel Hill, Chapel Hill, NC
5Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC
6Oregon Health & Science University, Portland, OR
7Erasmus University Medical Center, Rotterdam, Netherlands
8Hemophilia Centre, University Hospital Frankfurt, Frankfurt, Germany
9Oregon Health and Science University, Portland, OR
10Phoenix Children's Hospital, Phoenix, AZ
11uniQure Inc, Lexington, MA
12University of Michigan, Ann Arbor, MI